Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:activeIngredient |
gptkb:sintilimab
|
| gptkbp:administeredBy |
infusion
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:China
gptkb:classical_Hodgkin_lymphoma |
| gptkbp:ATCCode |
L01FF10
|
| gptkbp:CASNumber |
2147666-31-9
|
| gptkbp:developedBy |
gptkb:Eli_Lilly
gptkb:Innovent_Biologics |
| gptkbp:drugClass |
immunotherapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tyvyt (sintilimab)
|
| gptkbp:macromoleculeType |
PD-1 receptor
|
| gptkbp:mechanismOfAction |
PD-1 inhibitor
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
gptkb:programmed_cell_death_protein_1_(PD-1)
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
immunotherapy hepatocellular carcinoma esophageal squamous cell carcinoma |
| gptkbp:bfsParent |
gptkb:Innovent_Biologics
|
| gptkbp:bfsLayer |
7
|